Full-Time

Associate Director

Data Governance, FAIR, and AI-Readiness

Updated on 9/12/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Remote in USA

Remote

Bachelor's, Master's, PhD, Associate's

Category
Data & Analytics (1)
Required Skills
LLM
Machine Learning
RAG
Collibra
Data Governance

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Experience in the biotechnology or pharmaceutical industry, including understanding of regulated data, business processes, and compliance requirements.
  • Demonstrated leadership of enterprise data governance, data management, active metadata, data quality, or data product initiatives across business and technology teams.
  • Hands-on understanding of FAIR data principles and their practical application through active metadata, standards, semantics, interoperability, and access controls.
  • Experience establishing data governance operating models, including data ownership, stewardship, policy, standards, controls, and issue management.
  • Strong stakeholder management, communication, and influencing skills, with the ability to translate complex data topics into business value and decisions.
  • Doctorate degree and 2 years of Data Management, Information Systems, or related experience; or master's degree and 6 years of such experience; or bachelor's degree and 8 years of such experience; or associate degree and 10 years of such experience.
Responsibilities
  • Lead the enterprise Data Governance, FAIR, and data product strategy and roadmap, aligning investments to scientific and business priorities.
  • Establish a value-realization framework to measure business outcomes, adoption, and return on investment from data initiatives.
  • Execute the Enterprise Data Strategy, including data ownership, reusable data products, lifecycle management, data contracts, and adoption measures.
  • Evolve a federated governance operating model with clear decision rights, data ownership, stewardship accountabilities, data councils, data standards, and escalation paths.
  • Evolve FAIR maturity across the enterprise, including embedding FAIR practices in the data lifecycle, metadata standards, persistent identifiers, controlled vocabularies, and access patterns.
  • Advance active metadata, data catalog, lineage, business glossary, semantic and knowledge graph capabilities to improve discovery, context, interoperability, and trust.
  • Set governance policies and controls for data quality, observability, privacy, security, retention, and responsible use, ensuring fit-for-purpose data for regulated and AI-enabled use cases.
  • Partner with Data Architecture, Data Engineering, Digital, Security, Privacy, Legal, and business teams to operationalize governed data products across platforms and domains.
  • Enable responsible AI by defining and enforcing data readiness criteria.
  • Serve as the data engagement lead for an assigned business function, driving adoption of data management practices, including FAIR, to deliver measurable data improvements and business value.
  • Manage large-scale data programs, cross-functional initiatives, and external partners; communicate outcomes, risks, dependencies, and value realization to senior leadership.
Desired Qualifications
  • Experience implementing enterprise data strategy, scaling FAIR, data product operating models, and data contracts.
  • Knowledge of modern data management capabilities, including active metadata, data observability, lineage, ontologies, knowledge graphs, and policy-as-code.
  • Experience with master data, data catalogs, governance, quality, active metadata, and semantic technologies such as Collibra, Databricks Unity Catalog, Reltio, SciBite, or TopQuadrant.
  • Experience enabling responsible AI, including data readiness for machine learning, generative AI, retrieval-augmented generation, and AI agent use cases.
  • Ability to define measurable outcomes for data investments, including data product adoption, quality, time-to-discovery, reuse, compliance, and AI readiness.
  • Experience managing external partners and geographically distributed delivery teams in complex stakeholder environments.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.